Usca Ria LLC lifted its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 16.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,322 shares of the biotechnology company’s stock after purchasing an additional 1,312 shares during the period. Usca Ria LLC’s holdings in bluebird bio were worth $1,361,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its holdings in bluebird bio by 4.2% in the third quarter. Wells Fargo & Company MN now owns 70,117 shares of the biotechnology company’s stock valued at $10,237,000 after acquiring an additional 2,798 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new position in bluebird bio in the third quarter valued at approximately $106,000. Private Advisor Group LLC lifted its holdings in bluebird bio by 41.7% in the third quarter. Private Advisor Group LLC now owns 3,398 shares of the biotechnology company’s stock valued at $496,000 after acquiring an additional 1,000 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in bluebird bio by 2.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 64,693 shares of the biotechnology company’s stock valued at $9,445,000 after acquiring an additional 1,239 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in bluebird bio by 57.9% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 218,511 shares of the biotechnology company’s stock valued at $31,903,000 after acquiring an additional 80,145 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.
In other news, insider Jeffrey T. Walsh sold 20,000 shares of the company’s stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $175.40, for a total transaction of $3,508,000.00. Following the sale, the insider now owns 44,238 shares of the company’s stock, valued at $7,759,345.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Davidson sold 7,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $166.64, for a total value of $1,166,480.00. Following the sale, the insider now directly owns 31,905 shares in the company, valued at approximately $5,316,649.20. The disclosure for this sale can be found here. Insiders have sold 44,559 shares of company stock worth $7,147,478 in the last ninety days. Corporate insiders own 3.00% of the company’s stock.
bluebird bio stock opened at $134.18 on Wednesday. bluebird bio Inc has a twelve month low of $102.21 and a twelve month high of $236.17. The firm has a market cap of $7.19 billion, a PE ratio of -17.40 and a beta of 2.31.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the company earned ($1.73) earnings per share. The company’s revenue was up 49.2% on a year-over-year basis. As a group, research analysts forecast that bluebird bio Inc will post -10.83 EPS for the current fiscal year.
A number of research firms recently commented on BLUE. BidaskClub upgraded bluebird bio from a “strong sell” rating to a “sell” rating in a report on Friday, November 2nd. Cowen reiterated a “buy” rating on shares of bluebird bio in a report on Friday, November 2nd. Janney Montgomery Scott upgraded bluebird bio from a “neutral” rating to a “buy” rating and set a $170.00 price objective on the stock in a report on Monday. Piper Jaffray Companies reiterated a “buy” rating on shares of bluebird bio in a report on Thursday, August 2nd. Finally, Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $209.74.
TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/usca-ria-llc-buys-1312-shares-of-bluebird-bio-inc-blue.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Story: Risk Tolerance
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.